Sartorius Stedim Biotech and G-Con Manufacturing Announce Global Collaboration
Collaboration will support faster and more flexible facility construction and shortened time to market
Maik Jornitz, SSB’s Senior Vice President of Marketing for Bioprocess Solutions, stated, “The combined product portfolio will fundamentally change the way biopharmaceutical manufacturing processes will be designed and configured. Our Integrated Solutions unit will implement G-Con’s platform of modular clean-room systems into their designs. In addition, our teams will benefit from G-Con’s engineering and design expertise. Our vision is to create standardized unit operations, implemented into the self-contained G-Con modules. These modules can be used as individual process units or joined to an entire process.”
Barry Holtz, President of G-Con Manufacturing, stated, “Our common goal is to combine our complementary expertise to develop revolutionary solutions for the next generation of flexible, single-use manufacturing concepts. We couldn’t be more excited about having an agreement with a leader in single-use products like Sartorius Stedim Biotech.”
Effective immediately, G-Con’s modular containment units are available through SSB’s Integrated Solutions unit and will be rolled out globally in early 2012.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.